North Immunology to go public via $150M reverse merger with Aethlon
What's the deal? North ImmunologyDealroom has a profile for this one. Try Dealroom → has agreed to acquire Nasdaq-listed Aethlon MedicalDealroom has a profile for this one. Try Dealroom → in a $150 million reverse merger, announced on September 17, 2026. The all-stock transaction values the deal at an equity value of $150 million and will take North Immunology public.
The terms: Pre-merger North Immunology stockholders — including private placement investors — will own roughly 95.25% of the combined company, leaving Aethlon shareholders with about 4.75%. The combined entity will carry a pro forma equity value of around $346.5 million.
Why now? Concurrent with the deal, institutional and accredited investors agreed to buy about $180 million in North Immunology shares and warrants through a private placement backed by Bain Capital Life SciencesDealroom has a profile for this one. Try Dealroom →, Janus Henderson Investors and Deep Track CapitalDealroom has a profile for this one. Try Dealroom →. The merger requires at least $175 million of those proceeds to close.
What's the endgame? The combined company will operate as North Immunology and trade on the Nasdaq Capital Market under a new ticker, NRTX. North Immunology's existing management team will lead it, with its board — chaired by co-founder Daniel Schneeberger, managing partner of ADAR1 Capital ManagementDealroom has a profile for this one. Try Dealroom → — joined by new independent directors.
Aethlon shareholders will also receive a contingent value right for each share held, entitling them to any net proceeds from a future sale or licence of Aethlon's legacy Hemopurifier business.
What could go wrong? The deal hinges on multiple closing conditions, including approval from both companies' stockholders, SEC registration, Nasdaq listing approval, and antitrust clearance under the Hart-Scott-Rodino Act. If terminated under specified circumstances, Aethlon may owe a $300,000 fee, while North Immunology may owe $2 million.
The signal: Reverse mergers remain a favoured route for private biotechs to reach public markets without a traditional IPO, often paired with a large concurrent raise. North Immunology's $180 million private placement underscores how the structure lets companies list and refuel their balance sheets in a single move.
Read more: Fierce Biotech
Image credit: NavyMedicine
